# Nuclide record small-intestinal-net (indication). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/indications/small-intestinal-net/>
  a schema:MedicalCondition ;
  nuclide:kind "indication" ;
  schema:identifier "small-intestinal-net" ;
  schema:name "Small intestinal neuroendocrine tumours"@en ;
  schema:alternateName "Midgut neuroendocrine tumour"@en, "Small bowel NET"@en, "Ileal carcinoid"@en, "Jejunoileal neuroendocrine tumour"@en, "SI-NET"@en ;
  schema:description "Small intestinal neuroendocrine tumours are slow-growing hormone-producing tumours of the ileum and jejunum, often found only after they have spread to lymph nodes and the liver. Monthly somatostatin analogue injections control symptoms and growth, lutetium-177 dotatate is the main second treatment, and everolimus, cabozantinib and surgery fill in."@en ;
  schema:url <https://nuclide.cc/indications/small-intestinal-net/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Neuroendocrine_tumor> ;
  schema:citation <https://doi.org/10.1200/JCO.2009.22.8510>, <https://doi.org/10.1056/NEJMoa1607427>, <https://doi.org/10.1016/S0140-6736(24)00701-3>, <https://en.wikipedia.org/wiki/Neuroendocrine_tumor> ;
  nuclide:tag "subtype-page", "endocrine" ;
  nuclide:related <https://nuclide.cc/indications/grade-3-net/>, <https://nuclide.cc/indications/lung-net/>, <https://nuclide.cc/indications/pancreatic-net/>, <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:technologies <https://nuclide.cc/technologies/sstr-pet/>, <https://nuclide.cc/technologies/prrt/>, <https://nuclide.cc/technologies/radioligand-therapy/>, <https://nuclide.cc/technologies/radioembolisation-tare/> ;
  nuclide:targets <https://nuclide.cc/targets/sstr2/> ;
  nuclide:drugs <https://nuclide.cc/drugs/lutathera/>, <https://nuclide.cc/drugs/everolimus/>, <https://nuclide.cc/drugs/cabozantinib/>, <https://nuclide.cc/drugs/ga68-dotatate/>, <https://nuclide.cc/drugs/itm-11/> ;
  nuclide:terms <https://nuclide.cc/terms/net-grade-ki67/>, <https://nuclide.cc/terms/prrt-term/> ;
  nuclide:trials <https://nuclide.cc/trials/netter-1/>, <https://nuclide.cc/trials/nct03972488/>, <https://nuclide.cc/trials/radiant-3-4/>, <https://nuclide.cc/trials/cabinet/>, <https://nuclide.cc/trials/compete/> ;
  nuclide:keyPapers <https://nuclide.cc/key-papers/paper-netter-2-lancet-2024/>, <https://nuclide.cc/key-papers/paper-clarinet-lanreotide-nejm-2014/>, <https://nuclide.cc/key-papers/paper-netter-1-nejm-2017/> ;
  nuclide:pipeline <https://nuclide.cc/drugs/itm-11/>, <https://nuclide.cc/trials/compete/>, <https://nuclide.cc/drugs/ryz101/>, <https://nuclide.cc/trials/action-1/>, <https://nuclide.cc/drugs/alphamedix/>, <https://nuclide.cc/ideas/idea-net-antagonist-ligands/>, <https://nuclide.cc/ideas/idea-net-dosimetry-prrt/> ;
  nuclide:standardOfCare <https://nuclide.cc/technologies/sstr-pet/>, <https://nuclide.cc/drugs/ga68-dotatate/>, <https://nuclide.cc/terms/net-grade-ki67/>, <https://nuclide.cc/drugs/lutathera/>, <https://nuclide.cc/trials/nct03972488/>, <https://nuclide.cc/technologies/prrt/>, <https://nuclide.cc/drugs/lutathera/>, <https://nuclide.cc/trials/netter-1/>, <https://nuclide.cc/drugs/everolimus/>, <https://nuclide.cc/trials/radiant-3-4/>, <https://nuclide.cc/drugs/cabozantinib/>, <https://nuclide.cc/trials/cabinet/>, <https://nuclide.cc/technologies/radioembolisation-tare/>, <https://nuclide.cc/drugs/everolimus/>, <https://nuclide.cc/drugs/cabozantinib/>, <https://nuclide.cc/drugs/itm-11/>, <https://nuclide.cc/trials/compete/>, <https://nuclide.cc/drugs/ryz101/>, <https://nuclide.cc/trials/action-1/>, <https://nuclide.cc/drugs/alphamedix/> .